Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis.
atopic eczema
conjunctivitis
dupilumab
ocular adverse events
tear
Journal
Experimental dermatology
ISSN: 1600-0625
Titre abrégé: Exp Dermatol
Pays: Denmark
ID NLM: 9301549
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
24
05
2023
received:
12
04
2023
accepted:
09
06
2023
medline:
11
9
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
ppublish
Résumé
Dupilumab, blocking IL-4 and IL-13 signals, improves atopic dermatitis and Quality of Life but might be also associated with the occurrence of ocular adverse events (OAEs). The main objective of our prospective study was to characterize the cytokine and chemokine profile in the tear fluid of dupilumab-treated patients with moderate-to- severe atopic dermatitis and to identify biomarkers predicting the occurrence of ocular adverse events. Patients with moderate-to-severe AD underwent dermatological and ophthalmological evaluation at the baseline (T0) and week 16 or at the time of an eventual ocular adverse events (T1). A multiplex immunoassay measuring multiple cytokines and chemokines in the tear fluid extracted during ocular examination at both T0 and T1 was performed. Thirty-nine patients with moderate-to-severe AD and treated with dupilumab were included in the study. Baseline tear fluid levels revealed a significantly higher concentration of type 2 cytokines and chemokines in AD patients than healthy controls. The occurrence of ocular adverse events during dupilumab therapy was associated with a significant increase of IL-33 tear fluid levels and a significantly lower tear break-up time, this latter also identified as predictive factor. Our findings suggest that the ophthalmological examination should be considered a valid support to identify patients at risk of developing OAEs and to provide their appropriate management.
Substances chimiques
dupilumab
420K487FSG
Interleukin-33
0
Cytokines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1531-1537Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181:459-473.
Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335-2348.
De Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin a or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178:1083-1101.
Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389:2287-2303.
Blauvelt A, Wollenberg A, Eichenfield LF, et al. No increased risk of overall infection in adults with moderate-to-severe atopic dermatitis treated for up to 4 years with dupilumab. Adv Ther. 2023;40:367-380.
Touhouche AT, Cassagne M, Berard E, et al. Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study. J Eur Acad Dermatol Venereol. 2021;35:172-179.
Ivert LU, Wahlgren CF, Ivert L, Lundqvist M, Bradley M. Eye complications during dupilumab treatment for severe atopic dermatitis. Acta Derm Venereol. 2019;99:375-378.
Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81:143-151.
Vuillemey L, Febvay C, Puzenat E, et al. Analysis of cytokines in tear fluid from atopic dermatitis patients with dupilumab-associated ocular adverse events. J Eur Acad Dermatol Venereol. 2022;36:e195-e197.
Achten R, Thijs J, van Luijk C, et al. Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients. Clin Exp Allergy. 2023;53:239-243.
Bakker DS, Ter Linde JJM, Amini MM, et al. Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: a case series study. Allergy. 2021;76:3814-3817.
Bakker DS, Ariens LFM, Luijk C, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol. 2019;180:1248-1249.
Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184:437-449.
Safa G, Paumier V. Psoriasis induced by dupilumab therapy. Clin Exp Dermatol. 2019;44:e49-e50.
Bridgewood C, Wittmann M, Macleod T, et al. T helper 2 IL-4/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17-type diseases, including seronegative arthritis and Enthesitis/enthesopathy, but not to humoral autoimmune diseases. J Invest Dermatol. 2022;142:2660-2667.
Imai Y, Hosotani Y, Ishikawa H, et al. Expression of IL-33 in ocular surface epithelium induces atopic keratoconjunctivitis with activation of group 2 innate lymphoid cells in mice. Sci Rep. 2017;7:10053.
Hosotani Y, Yasuda K, Nagai M, et al. IL-33-induced keratoconjunctivitis is mediated by group 2 innate lymphoid cells in mice. Allergol Int. 2023;72:324-331. doi:10.1016/j.alit.2022.10.003
Katsuta M, Ishiuji Y, Matsuzaki H, et al. Transient increase in circulating basophils and eosinophils in dupilumab-associated conjunctivitis in patients with atopic dermatitis. Acta Derm Venereol. 2021;101:adv00483.
Rønnstad ATM, Hansen PM, Halling AS, et al. Factors associated with ocular surface disease and severity in adults with atopic dermatitis: a nationwide survey. J Eur Acad Dermatol Venereol. 2022;36:592-601.
Holly FJ, Lemp MA. Wettability and wetting of corneal epithelium. Exp Eye Res. 1971;11:239-250.
Tiffany JM, Pandit JC, Bron AJ. Soluble mucins and the physical properties of tears (abstract 3901). Invest Ophthalmol Vis Sci (ARVO Suppl). 1996;37:S845.
Kallarackal G, Ansari E, Amos N, et al. A comparative study to assess the clinical use of fluorescein meniscus time (FMT) with tear break up time (TBUT) and Schirmer's tests (ST) in the diagnosis of dry eyes. Eye. 2002;16:594-600.